Molecular structure of Neratinib, CAS Number: 698387-09-6
Neratinib (CAS 698387-09-6)
See product citations (4)
Alternate Names:
HKI-272
Application:
Neratinib is a potent and selective inhibitor of EGFR and HER2
CAS Number:
698387-09-6
Purity:
≥99%
Molecular Weight:
557.04
Molecular Formula:
C30H29ClN6O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Neratinib is a potent and selective inhibitor of EGFR and Neu(HER2) (IC50 = 92 nM and 59 nM, respectively) by preventing phosphorylation of these proteins by their respective kinases. Neratinib displays activity against a variety of cancer cell lines, including A431, 3T3, and MDA-MB-435. Neratinib is an inhibitor of c-Src and Flk-1.
Neratinib (CAS 698387-09-6) References
- Neratinib (HKI-272) in the treatment of breast cancer. | López-Tarruella, S., et al. 2012. Future Oncol. 8: 671-81. PMID: 22764764
- Profile of neratinib and its potential in the treatment of breast cancer. | Feldinger, K. and Kong, A. 2015. Breast Cancer (Dove Med Press). 7: 147-62. PMID: 26089701
- Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor. | Tiwari, SR., et al. 2016. Clin Breast Cancer. 16: 344-348. PMID: 27405796
- Neratinib: First Global Approval. | Deeks, ED. 2017. Drugs. 77: 1695-1704. PMID: 28884417
- Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer. | Miles, J. and White, Y. 2018. J Adv Pract Oncol. 9: 750-754. PMID: 31249722
- Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. | Xuhong, JC., et al. 2019. Am J Cancer Res. 9: 2103-2119. PMID: 31720077
- Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. | Nasrazadani, A. and Brufsky, A. 2020. Future Oncol. 16: 247-254. PMID: 32057254
- Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. | Oliveira, M., et al. 2020. Expert Rev Anticancer Ther. 20: 731-741. PMID: 32862744
- Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. | Zhao, M., et al. 2021. Clin Cancer Res. 27: 1681-1694. PMID: 33414137
- Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. | Dent, P., et al. 2021. Biochem Pharmacol. 190: 114642. PMID: 34077739
- The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer. | Chilà, G., et al. 2021. Drug Des Devel Ther. 15: 2711-2720. PMID: 34188449
- Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice. | Tao, G., et al. 2022. Toxicol Res (Camb). 11: 184-194. PMID: 35237423
- Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer. | Eli, LD. and Kavuri, SM. 2022. Cancer Drug Resist. 5: 873-881. PMID: 36627899
Inhibitor of:
AA987161, AChRα, AMBRA1, c-Src, CLU1, Dist1, EB2, EGF, EGFR, ephrin-B2, Epiregulin, EXT1, Flk-1, Gm20172, H2-22, HuR, Neu, Olr1124, Olr1404, Olr1562, Olr175, Olr309, Olr560, Olr649, Olr736, PCDHB16, PIG-M, and XPA.Activator of:
BTC, ErbB-4, and Neu.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Neratinib, 5 mg | sc-364549 | 5 mg | $92.00 | |||
Neratinib, 25 mg | sc-364549A | 25 mg | $214.00 | |||
Neratinib, 100 mg | sc-364549B | 100 mg | $383.00 | |||
Neratinib, 500 mg | sc-364549C | 500 mg | $755.00 | |||
Neratinib, 1 g | sc-364549D | 1 g | $1250.00 |